BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution

Core Insights - Teva Pharmaceutical Industries Limited is recognized as a promising stock under $100, with BofA raising its price target to $24 from $22 while maintaining a Buy rating [1] - The company has achieved its 10th consecutive quarter of year-over-year revenue growth, driven by its Pivot to Growth Strategy, targeting a 30% operating profit margin by 2027 [2] - Teva's innovative product portfolio has seen significant growth, with total revenues for Q2 2025 reaching $4.2 billion, marking a ~1% increase in local currency [2][3] Financial Performance - Teva's innovative portfolio collectively grew by ~26%, leading to an increased revenue outlook for key products [3] - AUSTEDO revenues were $498 million globally in Q2, up ~19% globally and ~22% in the US, with the 2025 revenue outlook raised to $2,000 to $2,050 million [3] - AJOVY global revenues reached $155 million, up ~31%, with the outlook increased to $630 to $640 million [3] - UZEDY revenues accelerated by ~120% to $54 million, with the outlook raised to $190 to $200 million [3] Strategic Initiatives - Teva is executing its Pivot to Growth Strategy, which has been a key driver of its recent revenue growth [2][3] - The company is focused on achieving a 30% operating profit margin by 2027 as part of its long-term strategy [2]